- GlobeNewswire•13 hours ago
MOUNTAIN VIEW, Calif., Oct. 20, 2016-- ChemoCentryx, Inc.,, today announced that effective October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., ...
- GlobeNewswire•3 days ago
--CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis--. --Findings reported at the American College of Gastroenterology 2016 Annual Meeting--. MOUNTAIN ...
- GlobeNewswire•4 days agoChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome (aHUS) at ASN Kidney Week 2016
MOUNTAIN VIEW, Calif., Oct. 17, 2016-- ChemoCentryx, Inc.,, today announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment of Atypical Hemolytic Uremic Syndrome ...
ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||2.50 x 4100|
|Ask||7.00 x 600|
|Day's Range||5.96 - 6.30|
|52wk Range||1.92 - 8.30|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.78|
|Avg Vol (3m)||176,795|
|Dividend & Yield||N/A (N/A)|